Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain

Opioids continue to be first-line pharmacotherapy for patients suffering from cancer pain. Unfortunately, subtherapeutic dosage prescribing of pain medications remains common, and many cancer patients continue to suffer and experience diminished quality of life. A large variety of therapeutic options are available for cancer pain patients. Analgesic pharmacotherapy is based on the patient’s self-report of pain intensity and should be tailored to meet the requirements of each individual. Most, if not all, cancer pain patients will ultimately require modifications in their opioid pharmacotherapy. When changes in a patient’s medication regimen are needed, adequate pain control is best maintained through appropriate dosage conversion, scheduling immediate release medication for withdrawal prevention, and providing as needed dosing for breakthrough pain. Transdermal opioids are noninvasive, cause less constipation and sedation when compared to oral opioids, and may improve patient compliance. A relative potency of 100:1 is recommended when converting the patient from oral morphine to transdermal fentanyl. Based on the limited data available, there is significant interpatient variability with transdermal buprenorphine and equipotency recommendations from oral morphine of 75:1–110:1 have been suggested. Cancer patients may require larger transdermal buprenorphine doses to control their pain and may respond better to a more aggressive 75–100:1 potency ratio. This review outlines the prescribing of transdermal fentanyl and transdermal buprenorphine including how to safely and effectively convert to and use them for those with cancer pain.

• Publication year

  2014

• Venue

  Journal of Pain Research

• Publication date

  2014-08-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/JPR.S36446PMID 25170278PMCID 4145844
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis

  2013cited by this paper
• Converting to Transdermal Fentanyl: Avoidance of Underdosing

  2013cited by this paper
• Oral morphine for cancer pain.

  2013cited by this paper
• A systematic review of randomized trials on the effectiveness of opioids for cancer pain.

  2012cited by this paper
• Treatment of Chronic Pain in Older People: Evidence-Based Choice of Strong-Acting Opioids

  2012cited by this paper
• Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.

  2012influential reference
• Treatment of Chronic Pain in Older People

  2012cited by this paper
• Practical considerations for optimal transdermal drug delivery.

  2012influential reference
• Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain

  2012cited by this paper
• Overdose deaths demand a new paradigm for opioid rotation.

  2012cited by this paper
• Buprenorphine 5, 10 and 20 μg/h Transdermal Patch

  2011cited by this paper
• Transdermal opioids for cancer pain

  2011influential reference
• European Palliative Care Research Collaborative pain guidelines: Opioid switching to improve analgesia or reduce side effects. A systematic review

  2011cited by this paper
• Opioid pharmacokinetic drug-drug interactions.

  2011influential reference
• Buprenorphine 5, 10 and 20lg/h Transdermal Patch A Review of its Use in the Management of Chronic Non-Malignant Pain

  2011cited by this paper
• Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review

  2011influential reference
• Transdermal opioids as front line treatment of moderate to severe cancer pain: a systemic review

  2011cited by this paper
• Buprenorphine TTS for children – a review of the drug’s clinical pharmacology

  2011cited by this paper
• Deaths With Transdermal Fentanyl Patches

  2010influential reference
• Safety Concerns Involving Transdermal Patches and Magnetic Resonance Imaging (MRI)

  2010cited by this paper
• Assessment and classification of cancer breakthrough pain: A systematic literature review

  2010cited by this paper
• Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.

  2010influential reference
• Transdermal Fentanyl: Not Ready for Front Line

  2009cited by this paper
• Equipotent doses to switch from high doses of opioids to transdermal buprenorphine

  2009influential reference
• Transdermal Fentanyl as A Front-Line Approach to Moderate-Severe Pain: A meta-analysis of Randomized Clinical Trials

  2009cited by this paper
• The management of cancer‐related breakthrough pain: Recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland

  2009cited by this paper
• Opioids Switching with Transdermal Systems in Chronic Cancer Pain

  2009cited by this paper
• Opioid rotation: the science and the limitations of the equianalgesic dose table.

  2009cited by this paper
• Establishing "best practices" for opioid rotation: conclusions of an expert panel.

  2009cited by this paper
• Transdermal fentanyl in cachectic cancer patients

  2009cited by this paper
• Opioid switching and rotation in primary care: implementation and clinical utility

  2009cited by this paper
• Pediatric Palliative Care

  2009cited by this paper
• Sustained‐release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management

  2008cited by this paper
• Adverse Effects of Transdermal Opiates Treating Moderate-Severe Cancer Pain in Comparison to Long-Acting Morphine: A Meta-Analysis and Systematic Review of the Literature

  2008cited by this paper
• Prevalence of pain in patients with cancer: a systematic review of the past 40 years.

  2007cited by this paper
• Challenging the equipotency calculation for transdermal buprenorphine: four case studies

  2007cited by this paper
• Opioid Rotation from High‐Dose Morphine to Transdermal Buprenorphine (Transtec®) in Chronic Pain Patients

  2007influential reference
• Oral morphine for cancer pain.

  2007cited by this paper
• Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine.

  2007influential reference
• Buprenorphine induces ceiling in respiratory depression but not in analgesia.

  2006cited by this paper
• Opioid-induced respiratory effects: new data on buprenorphine

  2006cited by this paper
• Opioid switching: a systematic and critical review.

  2006cited by this paper
• The Role of Opioids in Cancer Pain Management

  2005cited by this paper
• Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.

  2005cited by this paper
• World Health Organization guidelines for cancer pain: a reappraisal.

  2005cited by this paper
• The role of opioids in cancer pain

  2005cited by this paper
• Clinical experience with transdermal fentanyl for the treatment of cancer pain in Germany.

  2004cited by this paper
• Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers.

  2004influential reference
• Benefit-Risk Assessment of Transdermal Fentanyl for the Treatment of Chronic Pain

  2003cited by this paper
• An alternative algorithm for dosing transdermal fentanyl for cancer-related pain.

  2000cited by this paper
• Clinical Pharmacokinetics of Transdermal Opioids

  2000cited by this paper
• Opioid rotation for cancer pain

  1999cited by this paper
• Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain

  1996cited by this paper
• Opioid rotation in patients with cancer pain: A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine

  1996cited by this paper
• Transdermal fentanyl therapy: system design, pharmacokinetics and efficacy.

  1995cited by this paper
• Transdermal fentanyl in cancer pain: conversion from oral morphine.

  1995cited by this paper
• Opioid rotation for toxicity reduction in terminal cancer patients.

  1995cited by this paper
• Guidelines for the clinical use of transdermal fentanyl.

  1995influential reference
• The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation.

  1995cited by this paper
• Pain and its treatment in outpatients with metastatic cancer.

  1994cited by this paper
• Management of Pain in the Cancer Patient

  1993cited by this paper
• Management of pain in the cancer patient.

  1993cited by this paper
• Transdermal Fentanyl for Cancer Pain Repeated Dose Pharmacokinetics

  1993cited by this paper

• Pharmacological approach for pain management in palliative care outpatient department of a South Goa district hospital

  2025cites this paper
• Executive summary of the guideline for prescribing opioid analgesics for chronic non-cancer pain (third edition) by the Japan Society of Pain Clinicians

  2025cites this paper
• Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits

  2025cites this paper
• The Effect of Postoperative Single-Injection Adductor Canal Block in Total Knee Arthroplasty Under Spinal Anesthesia With Intraoperative Dexmedetomidine Infusion

  2024cites this paper
• Transdermal Opioids and the Quality of Life of the Cancer Patient: A Systematic Literature Review

  2024cites this paper
• Advances in Transdermal Drug Delivery Systems: A Bibliometric and Patent Analysis

  2023cites this paper
• Effects of hypnosis versus enhanced standard of care on postoperative opioid use after total knee arthroplasty: the HYPNO-TKA randomized clinical trial

  2022cites this paper
• Evaluation of Buprenorphine Rotation in Patients Receiving Long-term Opioids for Chronic Pain

  2021cites this paper
• Current strategies toward safer mu opioid receptor drugs for pain management

  2019cites this paper
• Fentanyl patch probably not related to amnesia in case

  2019cites this paper
• A Scoping Review of Transdermal Buprenorphine Use for Non-surgical Pain in the Pediatric Population

  2019cites this paper
• Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management.

  2019cites this paper
• Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option

  2018cites this paper
• Differences between Transdermal Fentanyl and Buprenorphine in the Elderly Hospice Patients

  2018cites this paper
• Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review

  2017influential citation
• Cancer pain management: recommendations from a Latin-American experts panel.

  2017cites this paper
• Palliative care in ovarian carcinoma patients—a personalized approach of a team work: a review

  2017cites this paper
• Evaluation of the Percutaneous Absorption of Ketamine HCl, Gabapentin, Clonidine HCl, and Baclofen, in Compounded Transdermal Pain Formulations, Using the Franz Finite Dose Model.

  2016cites this paper
• A rapid, simple and sensitive method for the determination and bioequivalence study of transdermal fentanyl in human plasma using liquid chromatography-electrospray ionization tandem mass spectrometry.

  2016cites this paper
• Safety of fentanyl initiation according to past opioid exposure among patients newly prescribed fentanyl patches

  2016cites this paper
• In vivo and in vitro evaluation of novel μ-opioid receptor agonist compounds.

  2015cites this paper
• Beneficios y efectos adversos del tratamiento con opioides en el dolor por cáncer.

  2015cites this paper
• Noninterventional Study of Transdermal Fentanyl (Fentavera) Matrix Patches in Chronic Pain Patients: Analgesic and Quality of Life Effects

  2015cites this paper
• Safety and Efficacy of Buprenorphine Patch in the Management of Chronic Pain

  2015cites this paper
• Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl

  2015cites this paper